Clinical-stage Australian Lifesciences company OncoSil Medical...

Clinical-stage Australian Lifesciences company OncoSil Medical (ASX:OSL) has made two new key appointments in preparation for the commercialisation of its OncoSilTM localised radiation treatment for cancer.


Daniel Kenny, CEO, featured in an interview recently heading up to the CE Mark, which can be accessed here.


The appointments include David James as global head of manufacturing operations, and Greg Rogers as manufacturing engineering manager.

James brings more than 20 years’ experience, including six years with leading cancer treatment company Sirtex Medical (ASX:SRX) as global operations manager.

Rogers has more than 27 years experience in leadership, operations, quality control and change management roles in the medical device and diagnostics sectors.

Daniel Kenny, CEO, commented:

“Both these appointments are pivotal additions to OncoSil Medical’s senior management team and will be integral to the company as it transitions it focus from the development phase to the commercialisation of OncoSilTM for the treatment of pancreatic and primary liver cancer (HCC).

"On behalf of the OncoSil team I would like to welcome David and Greg and we look forward to their strong, positive contributions as we continue to progress our commercialisation plans.”


Broker valuation

Wilson HTM has initiated coverage on OncoSil Medical with a Speculative Buy rating and a price target of A$0.35. The target is more than double the company's last traded price.